Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (27)
Fahad Alsohaibani, Musthafa Peedikayil, Abdulaziz Alshahrani, Ali Somily, Raed Alsulaiman, Nahla Azzam & Majid Almadi. (2023) Practice guidelines for the management of Helicobacter pylori infection: The Saudi H. pylori Working Group recommendations. Saudi Journal of Gastroenterology 29:6, pages 326-346.
Crossref
Crossref
Fariborz Mansour-Ghanaei, Behnam Masihipour, Mohammad Fathalipour, Soheil Hassanipour, Homayoon Sokhanvar, Alireza Mansour-Ghanaei, Mehrnaz Asgharnezhad & Farahnaz Joukar. (2022) The Efficacy, Safety, and Tolerability of Levofloxacin Quadruple Therapy for Helicobacter pylori Eradication: A Randomized, Double-Blind Clinical Trial. Evidence-Based Complementary and Alternative Medicine 2022, pages 1-7.
Crossref
Crossref
Masoud Keikha, Parvin Askari, Kiarash Ghazvini & Mohsen Karbalaei. (2022) Levofloxacin-based therapy as an efficient alternative for eradicating Helicobacter pylori infection in Iran: a systematic review and meta-analysis. Journal of Global Antimicrobial Resistance 29, pages 420-429.
Crossref
Crossref
Inés Ariño Pérez, Samuel J. Martínez-Domínguez, Enrique Alfaro Almajano, Patricia Carrera-Lasfuentes & Ángel Lanas. (2022) Management of Helicobacter Pylori Infection and Effectiveness Rates in Daily Clinical Practice in Spain: 2010–2019. Antibiotics 11:5, pages 698.
Crossref
Crossref
Wai Phyo Aung, Than Than Aye, Khin San Aye & Aye Mya Mya Kyaw. (2021)
Levofloxacin‐based
Helicobacter pylori
eradication in chronic dyspepsia
. GastroHep 3:6, pages 394-400.
Crossref
Crossref
Javier P. Gisbert. (2020) Optimization Strategies Aimed to Increase the Efficacy of Helicobacter pylori Eradication Therapies with Quinolones. Molecules 25:21, pages 5084.
Crossref
Crossref
M. Escobedo-Belloc & F. Bosques-Padilla. (2019) The rise of antibiotic resistance to Helicobacter pylori in Mexico: Is azithromycin plus levofloxacin the answer?. Revista de Gastroenterología de México (English Edition) 84:3, pages 271-273.
Crossref
Crossref
L. Ladrón-de-Guevara, L. Bornstein-Quevedo, S. González-Huezo, B. Castañeda-Romero, F.G. Costa & M. di Silvio-López. (2019) Helicobacter pylori eradication in Mexico with a levofloxacin-based scheme versus standard triple therapy: Results from an open-label, randomized, noninferiority phase IIIb trial. Revista de Gastroenterología de México (English Edition) 84:3, pages 274-283.
Crossref
Crossref
M. Escobedo-Belloc & F. Bosques-Padilla. (2019) El incremento en la resistencia de Helicobacter pylori a los antibióticos en México: ¿son la azitromicina más levofloxacina la respuesta?. Revista de Gastroenterología de México 84:3, pages 271-273.
Crossref
Crossref
L. Ladrón-de-Guevara, L. Bornstein-Quevedo, S. González-Huezo, B. Castañeda-Romero, F.G. Costa & M. di Silvio-López. (2019) Erradicación de Helicobacter pylori en México con un esquema basado en levofloxacina versus la triple terapia estándar: resultados de un estudio clínico de fase iiib, abierto, aleatorizado, de no inferioridad. Revista de Gastroenterología de México 84:3, pages 274-283.
Crossref
Crossref
Roy P. Liu, Roberta Romero, Jerzy Sarosiek, Christopher Dodoo, Alok K. Dwivedi & Marc J. Zuckerman. (2018) Eradication Rate of Helicobacter pylori on the US–Mexico Border Using the Urea Breath Test. Southern Medical Journal 111:1, pages 51-55.
Crossref
Crossref
Bor-Shyang Sheu, Ming-Shiang Wu, Cheng-Tang Chiu, Jing-Chuan Lo, Deng-Chyang Wu, Jyh-Ming Liou, Chun-Ying Wu, Hsiu-Chi Cheng, Yi-Chia Lee, Ping-I Hsu, Chun-Chao Chang, Wei-Lun Chang & Jaw-Town Lin. (2017)
Consensus on the clinical management, screening-to-treat, and surveillance of
Helicobacter pylori
infection to improve gastric cancer control on a nationwide scale
. Helicobacter 22:3, pages e12368.
Crossref
Crossref
Teresa Alarcón, Pedro Urruzuno, Maria Josefa Martínez, Diego Domingo, Laura Llorca, Ana Correa & Manuel López-Brea. (2017) Antimicrobial susceptibility of 6 antimicrobial agents in Helicobacter pylori clinical isolates by using EUCAST breakpoints compared with previously used breakpoints. Enfermedades infecciosas y microbiologia clinica (English ed.) 35:5, pages 278-282.
Crossref
Crossref
Teresa Alarcón, Pedro Urruzuno, Maria Josefa Martínez, Diego Domingo, Laura Llorca, Ana Correa & Manuel López-Brea. (2017) Antimicrobial susceptibility of 6 antimicrobial agents in Helicobacter pylori clinical isolates by using EUCAST breakpoints compared with previously used breakpoints. Enfermedades Infecciosas y Microbiología Clínica 35:5, pages 278-282.
Crossref
Crossref
Luís Eduardo S Fontes, Ana Luiza C Martimbianco, Christieny Chaipp Mochdece & Rachel Riera. (2017)
Proton pump inhibitor- and fluoroquinolone-based triple therapies for
Helicobacter pylori
eradication
. Cochrane Database of Systematic Reviews.
Crossref
Crossref
William D Chey, Grigorios I Leontiadis, Colin W Howden & Steven F Moss. (2017) ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. American Journal of Gastroenterology 112:2, pages 212-239.
Crossref
Crossref
Hyo Jun Ahn, Dong Pil Kim, Myeong Su Chu, Hyeon Jeong Yun, Seok-Hwan Kim, Seung Woo Lee & Dong Soo Lee. (2017)
Efficacy and Safety of the Triple Therapy Containing Ilaprazole, Levofloxacin, and Amoxicillin as First-Line Treatment in
Helicobacter pylori
Infections
. Gastroenterology Research and Practice 2017, pages 1-6.
Crossref
Crossref
Yiqiao Xin, Jan Manson, Lindsay Govan, Robin Harbour, Jenny Bennison, Eleanor Watson & Olivia Wu. (2016) Pharmacological regimens for eradication of Helicobacter pylori: an overview of systematic reviews and network meta-analysis. BMC Gastroenterology 16:1.
Crossref
Crossref
Anthony O'Connor, Javier P. Gisbert, Colm O'Morain & Spiros Ladas. (2015)
Treatment of
Helicobacter pylori
Infection 2015
. Helicobacter 20, pages 54-61.
Crossref
Crossref
Chuan Xie & Nong‐Hua Lu. (2014)
Review: Clinical Management of
Helicobacter pylori
Infection in China
. Helicobacter 20:1, pages 1-10.
Crossref
Crossref
Chang Seok BangGwang Ho Baik. (2015) Trends of Meta-analysis in Upper Gastrointestinal Diseases. The Korean Journal of Helicobacter and Upper Gastrointestinal Research 15:2, pages 80.
Crossref
Crossref
Su Young Kim. (2015)
Antibiotic treatment for
Helicobacter pylori
: Is the end coming?
. World Journal of Gastrointestinal Pharmacology and Therapeutics 6:4, pages 183.
Crossref
Crossref
Sang Wook Lee, Hyun Jung Kim & Jae Gyu Kim. (2015)
Treatment of
Helicobacter pylori
Infection in Korea: A Systematic Review and Meta-analysis
. Journal of Korean Medical Science 30:8, pages 1001.
Crossref
Crossref
Nabil Ben Chaabane & Hamad Saadoon Al-Adhba. (2015) Ciprofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: A randomized trial. Indian Journal of Gastroenterology 34:1, pages 68-72.
Crossref
Crossref
Jason Ferreira & Steven F. Moss. (2014) Current Paradigm and Future Directions for Treatment of Helicobacter pylori Infection. Current Treatment Options in Gastroenterology 12:4, pages 373-384.
Crossref
Crossref
Anthony O'Connor, Dino Vaira, Javier P. Gisbert & Colm O'Morain. (2014)
Treatment of
Helicobacter pylori
Infection 2014
. Helicobacter 19, pages 38-45.
Crossref
Crossref
Seng-Kee Chuah, Wei-Chen Tai, Chen-Hsiang Lee, Chih-Ming Liang & Tsung-Hui Hu. (2014)
Quinolone-Containing Therapies in the Eradication of
Helicobacter pylori
. BioMed Research International 2014, pages 1-5.
Crossref
Crossref